All In MedTech

Device Trial Radar · NCT02311582

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

Last checked: Nov 20, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Aug 5, 2015

Primary completion

Apr 15, 2024

Study completion Apr 15, 2024

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC
First posted
Dec 8, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The blood brain barrier (BBB) is a major obstacle to drug delivery in the treatment of malignant brain tumors including glioblastoma multiforme (GBM). MRI-guided laser ablation (MLA) has been noted to disrupt peritumoral the blood brain barrier (BBB), which may then lead to increased access of new tumor antigens to the lymphovascular system and vice versa of immune effector cells to the tumor for effective activation of the immune system, and tumor infiltration, respectively. Therefore, the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic combinatorial effect in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.

Conditions

  • Malignant Glioma

Interventions

  • MK-3475Biological

    Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).

  • MRI-guided laser ablationDevice

    MLA is a minimally invasive laser surgery, which employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of the tumor mass where it delivers hyperthermic ablation from the core to the rim.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of MK-3475 When Combined With MLA - Phase I OnlyTime frame: Completion of Cycle 1 (each cycle is 3 weeks)
  2. Progression-free Survival (PFS) - Phase II OnlyTime frame: Through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida

  • Washington University School of Medicine

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.